ADARx Pharmaceuticals, Inc. Stock

Stocks

Market Closed - Nasdaq 16:00:00 2026-11-13 EST			5-day change	1st Jan Change
14.20 ^USD	-4.76%		+7.33%	-

11-12	Earnings Flash (ADRX) ADARx Pharmaceuticals, Inc. Reports Q3 Revenue $2.2M	MT
11-12	Earnings Flash (ADRX) ADARx Pharmaceuticals, Inc. Reports Q3 Revenue $2.2M, vs. FactSet Est of $2.6M	MT

NasdaqUSD

Markets		Quality
Nasdaq	ADRX	Delayed
CBOE	ADRX	Real-time

11-12	Earnings Flash (ADRX) ADARx Pharmaceuticals, Inc. Reports Q3 Revenue $2.2M	MT
11-12	Earnings Flash (ADRX) ADARx Pharmaceuticals, Inc. Reports Q3 Revenue $2.2M, vs. FactSet Est of $2.6M	MT
10-20	ADARx Seen Positioned for 'Multiple Blockbuster Opportunities,' Morgan Stanley Says	MT
10-20	Morgan Stanley Initiates ADARx Pharmaceuticals at Overweight, With $32 Price Target	MT
10-20	UBS Initiates ADARx Pharmaceuticals at Buy, With $35 PT	MT
10-20	TD Cowen Initiates ADARx Pharmaceuticals at Buy	MT
10-20	Morgan Stanley Initiates ADARx Pharmaceuticals at Overweight	MT
10-20	JPMorgan Initiates ADARx Pharmaceuticals at Overweight With $38 Price Target	MT
09-30	Adarx Pharmaceuticals Insider Bought Shares Worth $1,045,772, According to a Recent SEC Filing	MT
09-30	ADARx Pharmaceuticals Insider Bought Shares Worth $27,200,000, According to a Recent SEC Filing	MT
09-27	ADARx Pharmaceuticals, Inc.(NasdaqGS:ADRX) added to NASDAQ Composite Index	CI
09-27	ADARx Pharmaceuticals, Inc. announced that it has received $89.344214 million in funding from AbbVie Inc.	CI
09-24	ADARx Pharmaceuticals, Inc. has completed an IPO in the amount of $446.25 million.	CI

10-20	ADARx Seen Positioned for 'Multiple Blockbuster Opportunities,' Morgan Stanley Says	MT
10-20	Morgan Stanley Initiates ADARx Pharmaceuticals at Overweight, With $32 Price Target	MT
10-20	UBS Initiates ADARx Pharmaceuticals at Buy, With $35 PT	MT
10-20	TD Cowen Initiates ADARx Pharmaceuticals at Buy	MT
10-20	Morgan Stanley Initiates ADARx Pharmaceuticals at Overweight	MT

11-12	ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates	GL
11-09	ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference	GL

Manager	Title	Age	Since
Zhen Li CEO	Chief Executive Officer	64	2019-11-30
Ryan Fisk DFI	Director of Finance/CFO	44	2026-02-28
Christopher Claeboe COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Zhen Li BRD	Director/Board Member	64	2019-11-30
Erez Chimovits CHM	Chairman	62	2020-04-30
Simeon George BRD	Director/Board Member	49	2021-06-30

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/28/26	SR One Capital Management LP	Conversion	Company	19,704,730	17.5846%
9/28/26	OrbiMed Advisors Private Equity	Conversion	Company	47,461,578	44.4391%
9/28/26	SR One Capital Management LP	Conversion	Company	19,704,730	17.5846%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADARX PHARMACEUTICALS, INC.	-4.76%	+7.33%	-	-	1.59B
WUXI APPTEC CO., LTD.	-2.69%	-0.48%	+51.67%	+69.09%	66.33B
ARGENX SE	-0.92%	+7.67%	+14.26%	+90.92%	60.62B
LONZA GROUP AG	0.00%	+0.39%	+20.52%	+98.45%	55.5B
BEONE MEDICINES AG	+0.14%	+2.35%	+13.08%	+109.47%	47.58B
IQVIA HOLDINGS INC.	-2.21%	-2.47%	+18.60%	+36.89%	43.69B
REVOLUTION MEDICINES, INC.	-2.30%	-10.40%	+167.61%	+776.79%	37.27B
CELLTRION, INC.	+2.15%	+1.42%	+15.17%	+56.49%	36.57B
GENMAB A/S	-2.32%	-2.24%	+75.52%	+52.70%	32.22B
INSMED INCORPORATED	+2.62%	+5.90%	-36.55%	+406.95%	26.58B
Average	-1.03%	+0.78%	+37.76%	+188.64%	41B
Weighted average by Cap.	-0.84%	+0.23%	+37.23%	+162.19%